Glenmark shares rise after US arm launches generic cancer drug
In short
Glenmark Pharmaceuticals shares rose after its US arm launched generic Axitinib Tablets. The drug is an authorized version of Pfizer’s cancer medicine INLYTA, and the launch followed regulatory approval.
The move matters because the new product can add to Glenmark’s US business and caught traders’ attention.
What the reporting says
Glenmark Pharmaceuticals’ shares rose after its US arm launched generic Axitinib Tablets, an authorized version of Pfizer’s cancer drug INLYTA. The launch followed regulatory approval.
Why it matters
Glenmark Pharmaceuticals’ stock moved higher after its US arm launched generic Axitinib Tablets, described as an authorized version of Pfizer’s INLYTA.